Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia

Famta, Paras; Shah, Saurabh; Vambhurkar, Ganesh B.; Srinivasarao, Dadi A.; Jain, Naitik; Begum, Nusrat; Sharma, Anamika; Shahrukh, Syed; Kumar, Kondasingh Charan; Bagasariya, Deepkumar; Khatri, Dharmendra Kumar; Singh, Shashi Bala; Srivastava, Saurabh

doi:10.1016/j.ejpb.2023.07.008

Cited by 13 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proteins as the drug delivery carrier have a long history in cancer therapy ( Hawkins et al, 2008 ; Jain et al, 2018 ). Paras Famta et al applied human serum albumin (HSA) to encapsulate ibrutinib (IB-NPs), and this IB-loaded albumin nanoparticle completed significant leukemic K562 cellular killing ( Famta et al, 2023 ). Ehsan Vafa et al utilized the bovine serum albumin protected gold nanozymes (BSA-Au nanozymes) as a nanodrug for the treatment of acute T-type lymphoblastic leukemia (Jurkat) by production of excessive ROS and effect on the expression of anti-apoptotic genes (Bcl-2) ( Vafa and Bazargan-Lari, 2021 ).…”

Section: The Application Of Nanocarriers-mediated Drug Deliverymentioning

confidence: 99%

The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment

Liu,

Yu,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Hematologic malignancies (HMs), also referred to as hematological or blood cancers, pose significant threats to patients as they impact the blood, bone marrow, and lymphatic system. Despite significant clinical strategies using chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, or immunotherapy, the five-year overall survival of patients with HMs is still low. Fortunately, recent studies demonstrate that the nanodrug delivery system holds the potential to address these challenges and foster effective anti-HMs with precise treatment. In particular, cell membrane camouflaged nanodrug offers enhanced drug targeting, reduced toxicity and side effects, and/or improved immune response to HMs. This review firstly introduces the merits and demerits of clinical strategies in HMs treatment, and then summarizes the types, advantages, and disadvantages of current nanocarriers helping drug delivery in HMs treatment. Furthermore, the types, functions, and mechanisms of cell membrane fragments that help nanodrugs specifically targeted to and accumulate in HM lesions are introduced in detail. Finally, suggestions are given about their clinical translation and future designs on the surface of nanodrugs with multiple functions to improve therapeutic efficiency for cancers.

show abstract